Differentiating effects of anisodamine on cognitive amelioration and peripheral muscarinic side effects induced by pilocarpine in mice

Neuroscience Letters

Volumn 344, Issue 3, 2003, Pages 173-176

  Wang, Hao ^a   Lu, Yang ^a   Chen, Hong Zhuan ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Alzheimer's disease; Anisodamine; Muscarinic acetylcholine receptor; Pilocarpine; Side effect

Indexed keywords

ANISODAMINE; MUSCARINIC AGENT; PILOCARPINE; SCOPOLAMINE;

AMNESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRADYCARDIA; COGNITION; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; HYPERSALIVATION; INTESTINE MOTILITY; LOW DRUG DOSE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 0037527563     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3940(03)00444-0     Document Type: Article

References (18)

1. Amenta F., Parnetti L., Gallai V., Wallin A. Treatment of cognitive dysfunction associated with Alzheimer's disease with cholinergic precursors. Ineffective treatments or inappropriate approaches? Mech. Ageing Dev. 122:2001;2025-2040.
2. Chen Q., Zeng Y. Anisodamine protects against neuronal death following cerebral ischemia in gerbils. Chin. Med. J. 113:2000;636-639.
3. Eglen R.M., Choppin A., Dillon M.P., Hegde S. Muscarinic receptor ligands and their therapeutic potential. Cur. Opin. Chem. Biol. 3:1999;426-432.
4. 1 selective cholinergic agonist, attenuates cognitive dysfunctions in an animal model of Alzheimer's disease. J. Pharmacol. Exp. Ther. 257:1991;292-299.
5. 1 muscarinic agonists as potential disease-modifying agents in Alzheimer's disease. Rationale and perspective. Ann. N. Y. Acad. Sci. 920:2000;315-320.
6. Greenlee W., Clader J., Asberom T., Mclombie S., Ford J., Guzik H., Kozlowski J. Muscarinic agonists and antagonists in the treatment of Alzheimer's disease. Farmaco. 56:2001;247-250.
7. Grutzendler J., Morris J.C. Cholinesterase inhibitors for Alzheimer's disease. Drugs. 61:2001;41-52.
8. Li Q.B., Pan R., Wang G.F., Tang S.X. Anisodamine as an effective drug to treat snakebites. J. Nat. Toxins. 8:1999;327-330.
9. 1 receptors. Pharm. Acta Helv. 74:2000;135-140.
10. Peng X., Coa S., Ke J. The effect of anisodamine on cerebral resuscitation of rats in acute cerebral ischemia from cardiac arrest. Chin. Med. Sci. J. 10:1995;237-239.
11. Seo H., Ferree A.W., Isacson O. Cortico-hippocampal APP and NGF levels are dynamically altered by cholinergic muscarinic antagonist or M1 agonist treatment in normal mice. Eur. J. Neurosci. 15:2002;493-506.
12. 1-selective muscarinic agonist: design, synthesis, and preclinical pharmacology. Pharm. Acta Helv. 74:2000;141-148.
13. Wagner L.E., Tomczuk B.E., Yanni J.M. Measurement of tachykinin induced salivation in conscious rats. J. Pharmacol. Methods. 26:1991;67-72.
14. 3H]quinuclidinyl benzilate binding to rat cerebral cortical and cardiac muscarinic cholinergic sites. I. Characterization and regulation of agonist binding to putative muscarinic subtypes. J. Pharmacol. Exp. Ther. 237:1986;411-418.
15. Winslow E. Evaluation of antagonism of aconitine-induced dysrhythmias in mice as a method of detecting and assessing antidysrhythmic activity. Br. J. Pharmacol. 71:1980;615-622.
16. Yu A.Y., Sun C. 6β-Acetoxy nortropane and its muscarinic receptor kinetics. Acta. Pharm. Sin. 11:1990;394-400.
17. Zhang J.T. New drugs derived from medicinal plants. Therapie. 57:2002;137-150.
18. Zhang S., Liu J., He L. Anisodamine (654-2) improves impaired cognitive function induced by experimental brain damage. Zhongguo. Yi. Xue. Yuan Xue. Bao. 17:1995;254-258.